ASX Announcement Page | 1 5 October, 2026 Melbourne, Australia CSL enters exclusive agreement for rare kidney and liver disease treatment CSL Limited (ASX:CSL; USOTC:CSLLY) today announces it has entered into an agreement with Alentis Therapeutics to co-develop and co-promote lixudebart, a...